“The problem, however, is that this future self is a projection of your present-day desires. When you’re defining what enough means, you’re effectively saying, “Given what I want today, I just need this much more of it to be satisfied […]
“Diversity is how we survive as a species. This is a quantifiable fact easily observed in the biological world. From niches to natural selection, diversity is the common theme of success for both the individual and the group.” ~ learn more
“A friend of mine was recently evaluating job offers and one was clearly a startup that was “going bad”. It was clear to me but not to them; I figured I would write a post spelling out some things I […]
Continuing with the “moving things around” theme: Here’s a profile of the tech startup Flexport, a tech-powered freight forwarder who was valued (overvalued?) at $8 billion last year. “It has designs on a bigger prize: owning the data layer for […]
Richard cofounded a tech company in the trucking space a couple years ago. He left pretty quickly, maybe a year in, and now runs a content marketing agency. So he likes to write! “Recently, I’ve been reflecting on my time […]
“According to Austin’s Public Works Department, the city is missing about 1,600 miles of sidewalk — a length of concrete that could stretch from here to Winnipeg, Canada.” ~ learn more
“The wheel on its own, while promising, is not very useful. Much like a doughnut, its most important feature is the hole in the center. If it wasn’t suitable for attaching a stable platform by combining it with an axle, […]
This might be the most ironic thing I’ve read in a while: “Several harm reduction advocates pointed out that drinking from borgs [“blackout rage gallons”] may actually mitigate the dangers of college drinking culture.” ~ learn more
“Despite enormous challenges facing many children around the globe, 2022 also brought good news. As we approach the end of the year, here are 10 areas of progress for children we can celebrate…” ~ learn more
“AbbVie’s Humira—a monoclonal antibody used to treat autoimmune disease—is the most financially successful drug ever to hit the market, bringing in $200 billion in revenue over its 20-year market rein.” Soon, it “will be saying goodbye to its 20-year throne […]